Novartis Gets Accelerated FDA Approval for Dabrafenib/Trametinib

The FDA says it granted accelerated approval to Novartis’s combination of dabrafenib (Tafinlar) and trametinib (Mekinist) to treat certain cancer patients.

• Applies to adult and pediatric patients at least six years old with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
• NOTE: Novartis Says Tafinlar With Mekinist Shows Efficacy in Study

NOTE

• Novartis AG fell 0.4% to CHF78.23 as of last close
  • The average 12-month price target of CHF90.75 is 16.0% above the current price
  • 16 buys, 14 holds, 3 sells

To view the source of ...